-
31.发明授权
公开(公告)号：EP3066078B1
公开(公告)日：2019-05-22
申请号：EP14702707.2
申请日：2014-01-16
发明人： MOSLIN, Ryan M. , WEINSTEIN, David S. , WROBLESKI, Stephen T. , ZHANG, Yanlei , TOKARSKI, John S. , MERTZMAN, Michael E. , LIU, Chunjian
IPC分类号： C07D213/82 , A61K31/44 , A61K31/4439 , A61K31/444 , A61K31/506 , C07D401/12 , C07D405/12 , C07D413/12 , C07D417/12 , A61P29/00 , A61P37/00
-
32.发明公开ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNALPHA RESPONSES 审中-公开阿尔茨海默病患者血清白介素12-，IL-23-UND / ODER IFN-ALPHA-REAKINGEN
公开(公告)号：EP3066078A1
公开(公告)日：2016-09-14
申请号：EP14702707.2
申请日：2014-01-16
发明人： MOSLIN, Ryan M. , WEINSTEIN, David S. , WROBLESKI, Stephen T. , ZHANG, Yanlei , TOKARSKI, John S. , MERTZMAN, Michael E. , LIU, Chunjian
IPC分类号： C07D213/82 , A61K31/44 , A61K31/4439 , A61K31/444 , A61K31/506 , C07D401/12 , C07D405/12 , C07D413/12 , C07D417/12 , A61P29/00 , A61P37/00
CPC分类号： A61K31/455 , A61K31/44 , A61K31/444 , A61K31/506 , C07B59/002 , C07B2200/05 , C07D213/56 , C07D213/82 , C07D401/12 , C07D405/12 , C07D413/12 , C07D417/12
摘要： or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα by acting on Tyk-2 to cause signal transduction inhibition.
摘要翻译： 具有下式（I）的化合物或其立体异构体或其药学上可接受的盐，其中R 1，R 2，R 3，R 4和R 5如本文所定义，可用于调节IL-12，IL-23和 /或IFNα作用于Tyk-2以引起信号转导抑制。
-
33.发明公开FIBRONECTIN BASED SCAFFOLD PROTEINS HAVING IMPROVED STABILITY 有权AUF FIBRONECTIN BASIERENDEGERÜSTPROTEINEMITERHÖHTERSTABILITÄT
公开(公告)号：EP2576615A2
公开(公告)日：2013-04-10
申请号：EP11731571.3
申请日：2011-05-26
CPC分类号： C07K14/78 , A61K38/00 , C07K14/71 , C07K14/7155 , C07K16/2863 , C07K2317/31 , C07K2317/34 , C07K2317/94 , C07K2318/20 , C07K2319/00 , C07K2319/30
摘要： The present application provides fibronectin based scaffold proteins associated with improved stability. The application also relates to stable formulations of fibronectin based scaffold proteins and the use thereof in diagnostic, research and therapeutic applications. The application further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising such polynucleotides.
摘要翻译： 本申请提供与改善的稳定性相关的基于纤连蛋白的支架蛋白。 该应用还涉及基于纤维连接蛋白的支架蛋白的稳定制剂及其在诊断，研究和治疗应用中的用途。 本申请还涉及包含这种蛋白质的细胞，编码这种蛋白质或其片段的多核苷酸，以及包含这种多核苷酸的载体。
-
34.发明授权5-AMINOINDENO[1,2-C]PYRAZOL-4-ONES AS ANTI-CANCER AND ANTI-PROLIFERATIVE AGENTS 有权5- AMINOINDENO [1,2-c]吡唑-4-酮作为抗肿瘤和生长抑制剂
公开(公告)号：EP1071668B1
公开(公告)日：2009-06-03
申请号：EP99918695.0
申请日：1999-04-20
IPC分类号： C07D231/54 , A61K31/41 , C07D409/12 , C07D403/12 , C07D401/12 , C07D417/12 , C07D413/12 , C07D413/14
CPC分类号： C07D405/12 , C07D231/54 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/14 , C07D405/04 , C07D409/04 , C07D409/12 , C07D409/14
摘要： The present invention relates to the synthesis of a new class of indeno [1,2-c]pyrazol-4-ones of formula (I), that are potent inhibitors of the class of enzymes known as cyclin dependent kinases, which relate to the catalytic subunits cdk1-7 and their regulatory subunits known as cyclines A-G. This invention also provides a novel method of treating cancer or other proliferative diseases by administering a therapeutically effective amount of one of these compounds or a pharmaceutically acceptable salt form thereof. Alternatively, one can treat cancer or other proliferative diseases by administering a therapeutically effective combination of one of the compounds of the present invention and one or more other known anti-cancer or anti-proliferative agents.
-
35.发明公开MOESIN, CAVEOLIN 1 AND YES ASSOCIATED PROTEIN 1 AS PREDICTIVE MARKERS OF RESPONSE TO DASATINIB IN BREAST CANCERS 有权膜突蛋白，小窝蛋白1和Yes相关蛋白响应于达沙替尼在乳腺癌1个AS预测指标
公开(公告)号：EP1951906A2
公开(公告)日：2008-08-06
申请号：EP06839824.7
申请日：2006-11-10
IPC分类号： C12Q1/68
CPC分类号： G01N33/57415 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/154 , C12Q2600/158 , G01N2333/52 , G01N2333/705
摘要： The invention described herein relates to methods and compositions useful in the diagnosis, treatment and management of cancers that express particular genes, including the moesin, caveolin 1, and/or yes-associated protein 1 genes.
-
公开(公告)号：EP1772452A3
公开(公告)日：2007-07-04
申请号：EP06076915.5
申请日：2001-02-15
发明人： Decicco, Carl P. , Nelson, David J. , Barrett, John A. , Carpenter, Alan P. , Duran, James J. , Rajopadhye, Milind
IPC分类号： C07D413/12 , C07D267/00 , C07D401/12 , C07D401/14 , C07F9/09 , A61K31/395 , A61K31/4427 , A61K31/661 , A61K51/04 , A61P35/00 , A61P29/00
CPC分类号： A61K49/14 , A61K49/0002 , A61K49/085 , A61K49/10 , A61K51/088 , C07D207/26 , C07D213/82 , C07D267/00 , C07D401/12 , C07D401/14 , C07D413/12 , C07F9/6527
摘要： The present invention describes novel compounds comprising: 1-10 targeting moieties; a chelator (Ch); and 0-1 linking groups (Ln) between the targeting moiety and chelator; wherein the targeting moiety is a matrix metalloproteinase inhibitor; and wherein the chelator is capable of conjugating to a cytotoxic radioisotope. The present invention also provides novel compositions of the compounds of the invention, kits, and their uses in treatment of diseases associated with MMPs.
-
公开(公告)号：EP1140203B1
公开(公告)日：2007-05-23
申请号：EP99967442.7
申请日：1999-12-17
CPC分类号： C07D401/14 , A61K49/0002 , B01J2219/00317 , B01J2219/00495 , B01J2219/00659 , B01J2219/00707 , C07D401/12 , C07K5/0205 , C07K5/0215 , C07K5/06139 , C07K5/06191 , C40B60/14 , G01N25/482 , G01N25/4866
摘要： The present invention describes novel compounds of the formula (Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention also provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention also provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
-
38.发明公开UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS 有权FOR P2Y1受体的痛苦血栓SUITABLE尿素拮抗剂治疗
公开(公告)号：EP1751113A1
公开(公告)日：2007-02-14
申请号：EP05747470.2
申请日：2005-05-11
发明人： CHAO, Hannguang J. , TUERDI, Huji , HERPIN, Timothy , ROBERGE, Jacques Yves , LIU, Yalei , LAWRENCE, R. Michael , REHFUSS, Robert P. , CLARK, Charles G. , QIAO, Jennifer X. , GUNGOR, Timur , LAM, Patrick Y.S. , WANG, Tammy C. , RUEL, Rejean , L'HEUREUX, Alexandre L. , THIBEAULT, Carl , BOUTHILLIER, Gilles , SCHNUR, Dora M.
IPC分类号： C07D231/50 , C07D231/40 , C07D213/40 , C07D413/12 , C07D401/12 , C07D405/12 , C07D417/12 , C07D333/36 , A61K31/444 , A61P7/02
CPC分类号： C07D409/14 , C07C275/30 , C07C275/32 , C07D213/40 , C07D213/75 , C07D213/89 , C07D231/40 , C07D231/50 , C07D237/22 , C07D333/36 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/12 , C07D417/12 , C07F7/1856
摘要： The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
-
39.发明公开BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO EPIDERMAL GROWTH FACTOR RECEPTOR MODULATORS IN NON-SMALL CELL LUNG CANCER 审中-公开生物标志物和方法，用于非小确定SENSITIVITY TO表皮生长因子受体的调节剂
公开(公告)号：EP1735463A2
公开(公告)日：2006-12-27
申请号：EP05738675.7
申请日：2005-03-28
IPC分类号： C12Q1/68 , A61K39/395 , A61K49/14 , C07K16/28
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158
摘要： EGFR biomarkers useful in a method for identifying a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) exposing a biological sample from the mammal to the EGFR modulator and (b) measuring in the biological sample the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the EGFR modulator indicates that the mammal will respond therapeutically to the method of treating cancer.
-
公开(公告)号：EP1706398A1
公开(公告)日：2006-10-04
申请号：EP05711663.4
申请日：2005-01-20
发明人： HERPIN, Timothy, F. , MORTON, George, C. , REHFUSS, Robert, P. , LAWRENCE, R., Michael , POSS, Michael, A. , ROBERGE, Jacques, Y. , GUNGOR, Timur
IPC分类号： C07D401/12 , C07D413/12 , C07D409/14 , C07D401/14 , C07D491/04 , C07D417/12 , C07D405/14 , C07D235/30 , C07D471/04 , C07D417/14 , C07D513/04 , C07D413/14 , C07D409/12 , A61K31/4184 , A61K31/423
CPC分类号： C07D401/12 , C07D235/30 , C07D401/14 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04 , C07D491/04 , C07D513/04
摘要： The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
-
-
-
-
-
-
-
-
-
搜索结果
180 条记录 (耗时 0.046 秒)
